Morgan Stanley
STLN

Morgan Stanley’s Starling Oncology STLN Stock Holding History

Morgan Stanley’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$734K Sell
135,085
-36,855
-21% -$155K ﹤0.01% 5374
2026
Q1 		$528K Sell
171,940
-50,113
-23% -$154K ﹤0.01% 5457
2025
Q4 		$791K Buy
222,053
+131,037
+144% +$486K ﹤0.01% 5302
2025
Q3 		$318K Sell
91,016
-84,357
-48% -$289K ﹤0.01% 5702
2025
Q2 		$360K Buy
175,373
+144,885
+475% +$362K ﹤0.01% 5616
2025
Q1 		$34.8K Buy
30,488
+96
+0.3% +$74 ﹤0.01% 6387
2024
Q4 		$9.39K Hold
30,392
– – ﹤0.01% 6826
2024
Q3 		$9.94K Buy
30,392
+1,052
+4% +$436 ﹤0.01% 6722
2024
Q2 		$13.5K Sell
29,340
-41,214
-58% -$35.2K ﹤0.01% 6575
2024
Q1 		$111K Buy
70,554
+46,570
+194% +$88.5K ﹤0.01% 5944
2023
Q4 		$48.9K Buy
23,984
+18,522
+339% +$32.1K ﹤0.01% 6172
2023
Q3 		$7.65K Sell
5,462
-4,038
-43% -$4.18K ﹤0.01% 6807
2023
Q2 		$5.23K Sell
9,500
-8,506
-47% -$4.5K ﹤0.01% 6977
2023
Q1 		$12.2K Sell
18,006
-408
-2% -$520 ﹤0.01% 6818
2022
Q4 		$30.4K Buy
18,414
+16,989
+1,192% +$47.7K ﹤0.01% 6510
2022
Q3 		$6K Buy
1,425
+222
+18% +$1.3K ﹤0.01% 7219
2022
Q2 		$6K Sell
1,203
-3,272
-73% -$23.8K ﹤0.01% 7370
2022
Q1 		$33K Buy
4,475
+3,543
+380% +$23.9K ﹤0.01% 6905
2021
Q4 		$9K Buy
+932
New +$8.28K ﹤0.01% 7512
2021
Q3 		– Sell
-20,098
Closed -$200K – 8024
2021
Q2 		$200K Sell
20,098
-4,984
-20% -$50.2K ﹤0.01% 6017
2021
Q1 		$250K Buy
25,082
+24,062
+2,359% +$256K ﹤0.01% 5532
2020
Q4 		$11K Buy
1,020
+945
+1,260% +$9.73K ﹤0.01% 6609
2020
Q3 		$1K Buy
+75
New +$779 ﹤0.01% 6673

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley's STLN Position: Q2 2026 in Review

Morgan Stanley reduced its Starling Oncology (STLN) stake by 21% in Q2 2026, selling an estimated $155K and leaving 135,085 shares worth $734K. The position accounts for ﹤0.01% of the portfolio, ranked #5374.

Morgan Stanley first reported a position in STLN in Q3 2020 and has held it in 23 quarters since. The position peaked at $791K in Q4 2025. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Morgan Stanley held 135,085 shares of Starling Oncology worth $734K as of Q2 2026.
  • Morgan Stanley sold 36,855 Starling Oncology shares in Q2 2026, an estimated $155K.
  • Starling Oncology made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5374 holding.
  • Morgan Stanley first reported a position in Starling Oncology in Q3 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Starling Oncology position peaked at $791K in Q4 2025.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.